Argatroban is a synthetic direct thrombin inhibitor used for the prevention and treatment of thrombosis related to heparin use. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention.
- Mechanism
- Curator reviewed
Argatroban exerts its anticoagulant effects by inhibiting thrombin-catalyzed or -induced reactions, including fibrin formation; activation of coagulation factors V, VIII, and XIII; protein C; and platelet aggregation.
- Primary indication
- Argatroban is indicated for prevention and treatment of thrombosis caused by heparin-induced thrombocytopenia (HIT).Curator reviewed · 3 structured indications
- Formula / weight
- C23H36N6O5S · 508.64 g/mol (avg)
- First approval
- Canada, 2020 · United States, 2000
Resolves to
KXNPVXPOPUZYGB-IOVMHBDKSA-NSMILESC[C@@H]1CCN([C@H](C1)C(O)=O)C(=O)[C@H](CCCNC(N)=N)NS(=O)(=O)C1=CC=CC2=C1NCC(C)C2What you can answer from here — as of September 23, 2026
Which drugs share a target with Argatroban, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account